Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
42,194,093
-
Total 13F shares
-
39,323,641
-
Share change
-
+7,143,039
-
Total reported value
-
$1,429,414,516
-
Put/Call ratio
-
23%
-
Price per share
-
$36.35
-
Number of holders
-
155
-
Value change
-
+$260,798,405
-
Number of buys
-
103
-
Number of sells
-
39
Institutional Holders of Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) as of Q1 2024
As of 31 Mar 2024 Tarsus Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TARS) had 155 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 39,323,641 shares of stock of the company.
Largest 10 holders included RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, BlackRock Inc., MORGAN STANLEY, TANG CAPITAL MANAGEMENT LLC, Cormorant Asset Management, LP, COWEN AND COMPANY, LLC, VANGUARD GROUP INC, Frazier Life Sciences Management, L.P., and JENNISON ASSOCIATES LLC.
This table shows 155 institutional shareholders of the security as of 31 Mar 2024.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.